These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 34313699)

  • 1. Anabolic Therapy for Osteoporosis.
    Ensrud KE; Schousboe JT
    JAMA; 2021 Jul; 326(4):350-351. PubMed ID: 34313699
    [No Abstract]   [Full Text] [Related]  

  • 2. Abaloparatide: Recombinant human PTHrP (1-34) anabolic therapy for osteoporosis.
    Chew CK; Clarke BL
    Maturitas; 2017 Mar; 97():53-60. PubMed ID: 28159062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abaloparatide and the Spine: A Narrative Review.
    Thompson JC; Wanderman N; Anderson PA; Freedman BA
    Clin Interv Aging; 2020; 15():1023-1033. PubMed ID: 32636617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Parathyroid hormone and parathyroid hormone-related protein analogs as therapies for osteoporosis.
    Augustine M; Horwitz MJ
    Curr Osteoporos Rep; 2013 Dec; 11(4):400-6. PubMed ID: 24078470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anabolic agents: what is beyond osteoporosis?
    Liu Y; Levack AE; Marty E; Or O; Samuels BP; Redko M; Lane JM
    Osteoporos Int; 2018 May; 29(5):1009-1022. PubMed ID: 29627891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms of anabolic therapies for osteoporosis.
    Canalis E; Giustina A; Bilezikian JP
    N Engl J Med; 2007 Aug; 357(9):905-16. PubMed ID: 17761594
    [No Abstract]   [Full Text] [Related]  

  • 7. Abaloparatide, the second generation osteoanabolic drug: Molecular mechanisms underlying its advantages over the first-in-class teriparatide.
    Bhattacharyya S; Pal S; Chattopadhyay N
    Biochem Pharmacol; 2019 Aug; 166():185-191. PubMed ID: 31136739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New anabolic therapies for osteoporosis.
    Minisola S; Cipriani C; Occhiuto M; Pepe J
    Intern Emerg Med; 2017 Oct; 12(7):915-921. PubMed ID: 28780668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of PTH in the treatment of osteoporosis.
    Borba VZ; Mañas NC
    Arq Bras Endocrinol Metabol; 2010 Mar; 54(2):213-9. PubMed ID: 20485911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Parathyroid hormone as an anabolic skeletal therapy.
    Rubin MR; Bilezikian JP
    Drugs; 2005; 65(17):2481-98. PubMed ID: 16296873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Shoring Up Osteoporosis Management: A Fresh Start?
    Furr N; Ulmer A; Cardon B
    J Am Board Fam Med; 2024; 37(3):490-493. PubMed ID: 39142871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Osteoanabolic and dual action drugs.
    Tabacco G; Bilezikian JP
    Br J Clin Pharmacol; 2019 Jun; 85(6):1084-1094. PubMed ID: 30218587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of parathyroid hormone in the treatment of osteoporosis.
    Girotra M; Rubin MR; Bilezikian JP
    Rev Endocr Metab Disord; 2006 Jun; 7(1-2):113-21. PubMed ID: 17043762
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New therapeutic targets for osteoporosis: beyond denosumab.
    Lim V; Clarke BL
    Maturitas; 2012 Nov; 73(3):269-72. PubMed ID: 22925430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New therapeutic targets for osteoporosis.
    Anagnostis P; Gkekas NK; Potoupnis M; Kenanidis E; Tsiridis E; Goulis DG
    Maturitas; 2019 Feb; 120():1-6. PubMed ID: 30583758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative efficacy of bone anabolic therapies in women with postmenopausal osteoporosis: A systematic review and network meta-analysis of randomized controlled trials.
    Hernandez AV; Pérez-López FR; Piscoya A; Pasupuleti V; Roman YM; Thota P; Herrera A
    Maturitas; 2019 Nov; 129():12-22. PubMed ID: 31547908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination/sequential therapies for anabolic and antiresorptive skeletal agents for osteoporosis.
    Bilezikian JP; Rubin MR
    Curr Osteoporos Rep; 2006 Mar; 4(1):5-13. PubMed ID: 16527002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigational anabolic agents for the treatment of osteoporosis: an update on recent developments.
    Dede AD; Makras P; Anastasilakis AD
    Expert Opin Investig Drugs; 2017 Oct; 26(10):1137-1144. PubMed ID: 28836858
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anabolic Therapy for the Treatment of Osteoporosis in Childhood.
    Ward LM; Rauch F
    Curr Osteoporos Rep; 2018 Jun; 16(3):269-276. PubMed ID: 29589203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of anabolic agents in the treatment of osteoporosis: a clinical update.
    Inderjeeth CA; Inderjeeth DC
    Curr Opin Endocrinol Diabetes Obes; 2024 Aug; 31(4):157-163. PubMed ID: 38752851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.